Clinical Trial: IL-12 Genetically Engineered Myeloid Cells in Participants With Relapsed, Refractory Solid Tumors

U.S., June 30 -- ClinicalTrials.gov registry received information related to the study (NCT07672483) titled 'IL-12 Genetically Engineered Myeloid Cells in Participants With Relapsed, Refractory Solid Tumors' on June 26.

Brief Summary: Background:

Myeloid cells are a type of immune cell found in most tumors. Interleukin 12 (IL-12) is a protein the immune system makes that can help kill tumor cells. Researchers want to know if myeloid cells that have been genetically engineered to produce IL-12 (IL-12 GEMys) can attack cancer cells in solid tumors.

Objective:

To test IL-12 GEMys in people with cancer.

Eligibility

People aged 18 years and older with cancer that returned or failed to respond to treatment.

Design:

Participants will be sc...